Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

SpO2 Verification Study - Philips Nasal Alar With Nellcor OxiMax SpO2 Board (453564624031)

14 juli 2026 bijgewerkt door: Philips Clinical & Medical Affairs Global
The primary purpose of the clinical investigation is to verify the SpO2 accuracy of the Philips AlarX5 SpO2 sensor with Nellcor OxiMax SpO2 Board.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

To verify the SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) with the Nellcor OxiMax pulse oximetry technology during non-motion conditions over the range of 70-100% SaO2, when compared with the reference SaO2 obtained from CO-Oximetry analysis of arterial blood samples.

Studietype

Observationeel

Inschrijving (Werkelijk)

43

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Colorado
      • Louisville, Colorado, Verenigde Staten, 80027
        • Element Materials Technology

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Ja

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

The study population will include a minimum of 36 to 72 healthy adult volunteers.

Beschrijving

Inclusion Criteria:

  • Participant must have the ability to understand and provide written informed consent
  • Participant is an adult between 18-50 years of age
  • Participant must be willing and able to comply with study procedures and duration
  • Participant is a non-smoker or who has not smoked within 2 days prior to the study

Exclusion Criteria:

  • Participant is considered as being morbidly obese (defined as BMI >39.5)
  • Compromised circulation (i.e., Raynaud's Syndrome), injury, or physical malformation of fingers, hands, nose, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. Tattoos (e.g. permanent, Henna) or artificial dyes (e.g. spray tan, artificial tanning lotion) in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)
  • Females who are pregnant
  • Females who are trying to get pregnant with confirmation of positive urine pregnancy test
  • Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels >3% as assessed with a Masimo Radical 7 (Rainbow)
  • Participants with known respiratory conditions such as: (self-reported)

    • uncontrolled / severe asthma
    • flu
    • pneumonia / bronchitis
    • shortness of breath / respiratory distress
    • unresolved respiratory or lung surgery
    • emphysema, COPD, lung disease
    • recent COVID with hospitalization
  • Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)

    • high blood pressure: systolic >140 mmHg or diastolic >90 mmHg on 3 consecutive readings (reviewed during health screen)
    • have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA)
    • chest pain (angina)
    • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
    • previous heart attack
    • blocked artery
    • unexplained shortness of breath
    • congestive heart failure (CHF)
    • history of stroke
    • transient ischemic attack
    • carotid artery disease
    • myocardial ischemia
    • myocardial infarction
    • cardiomyopathy
    • implantable active medical device such as pacemaker or automatic defibrillator
  • Participants with self-reported health conditions

    • diabetes
    • uncontrolled thyroid disease
    • kidney disease / chronic renal impairment,
    • history of seizures (except childhood febrile seizures)
    • epilepsy
    • history of unexplained syncope
    • recent history of frequent migraine headaches
    • recent symptomatic head injury (within the last 2 months) with continued symptoms
    • cancer requiring chemotherapy, radiation, or current treatment - Participants with known clotting disorders (self reported)
    • history of bleeding disorders or personal history of prolonged bleeding from injury
    • history of blood clots
    • hemophilia
    • current use of blood thinner: prescription or daily use of aspirin
    • Sickle Cell Trait or Disease - Participants with self-reported dermatological conditions at sensor application sites
    • severe dermatitis
    • hyperkeratosis
    • nail fungus - Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self reported)
  • Participants with severe allergies to iodine (only applicable if iodine is used)
  • Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine)
  • Participants with allergies to ultrasound gel
  • Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio <0.4)
  • Unwillingness or inability to remove nail polish, nail jewelry, or artificial nails from test digits. Bruised nail bed of test digits.
  • Unwillingness or inability to remove makeup, creams, lotions, sunscreen, or powders from application sites on the nose or ear.
  • Unwillingness or inability to cut/trim fingernail(s) of test digits if determined length will interfere with correct application of the sensor
  • Piercing at application site of the ear or nose sensors that may interfere with correct placement of sensor
  • Participants received colored intravascular dye within the past 48 hours (e.g. Indocyanine green, methylene blue, dyes used in cardiac output monitoring)
  • Surgical hardware in pathway of Device Under Test
  • Other known health conditions should be considered upon disclosure

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Healthy Volunteers
Participants are healthy, non-smoking (or has refrained from smoking for 2 days) competent adults, ages 18 to 50 years.

The experimental Philips AlarX5 SpO2 sensor will be tested with Nellcor OxiMax pulse oximetry technology. The AlarX5 SpO2 sensor will be connected via an adapter cable to an IntelliVue X3 Patient Monitor integrated with a Nellcor OxiMax SpO2 Board. Within the study, biomedical/health related outcomes as it relates to the healthy volunteers are not evaluated. The data collected will be used to evaluate how accurate the pulse oximeter (DUT) is to the reference.

Devices under test are listed below:

  • Nellcor OxiMax SpO2 Board (453564624031) integrated within Philips IntelliVue X3 Patient Monitor (867030)
  • Philips AlarX5, Experimental SpO2 sensor based on the Nasal Alar design (nasal ala and earlobe placement)
  • Philips M1943NL SpO2 Adapter Cable (3m)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) compared to arterial oxygen saturation.
Tijdsspanne: Up to 6 weeks
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (nasal ala application) compared to arterial oxygen saturation.
Up to 6 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (earlobe placement) during non-motion conditions.
Tijdsspanne: Up to 6 weeks
Measurement and comparison of SpO2 accuracy of the AlarX5 SpO2 sensor (earlobe placement) during non-motion conditions.
Up to 6 weeks

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Evaluation of the pigmentation bias of the AlarX5 SpO2 sensor (nasal ala and earlobe application).
Tijdsspanne: Up to 6 weeks
Non-disparate performance for the AlarX5 SpO2 sensor.
Up to 6 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

28 mei 2026

Primaire voltooiing (Werkelijk)

29 juni 2026

Studie voltooiing (Werkelijk)

29 juni 2026

Studieregistratiedata

Eerst ingediend

16 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

25 juni 2026

Eerst geplaatst (Werkelijk)

2 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

14 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • SEF-2025-301123

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

This is currently under consideration.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren